alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
_________________________________________ 

 

 

 

 

 

 

Order Michigan Supreme Court 

Lansing, Michigan 

March 25, 2008 Clifford W. Taylor,

 Chief Justice 

Michael F. Cavanagh 

Elizabeth A. Weaver 

135933 (3) Marilyn Kelly 

Maura D. Corrigan 

Robert P. Young, Jr. 

Stephen J. Markman,

 Justices 

CARLETUS WILLIAMS, 

Plaintiff, 

v SC: 135933 

 AGC: 3121/07 

ATTORNEY GRIEVANCE COMMISION,

 Defendant. 

___________________________________ 

On order of the Chief Justice, the motion to waive fees is considered and it 

is DENIED because MCL 600.2963 requires that a prisoner pursuing a civil action be 

liable for filing fees. 

Within 21 days of the certification of this order, plaintiff shall pay to the 

Clerk of the Court the initial partial filing fee of $26.00, shall submit a copy of this order 

with the payment, and shall refile the copy of the pleadings which is being returned 

with this order. Failure to comply with this order shall result in the appeal not being 

filed in this Court. 

If plaintiff timely files the partial fee and refiles the pleadings, monthly 

payments shall be made to the Department of Corrections in an amount of 50 percent of 

the deposits made to plaintiff’s account until the payments equal the balance due of 

$349.00. This amount shall then be remitted to this Court.

 Pursuant to MCL 600.2963(8) plaintiff shall not file further appeals in this 

Court until the entry fee in this case is paid in full. 

The Clerk of the Court shall furnish two copies of this order to plaintiff and 

return plaintiff’s pleadings with this order. 

jm 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

March 25, 2008 

Clerk
II 

112TH CONGRESS 

2D SESSION S. 2977 

To extend the temporary suspension of duty on 1,1,2-2-tetrafluoroethene, 

oxidized, polymerized. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on 1,1,2-2- 

tetrafluoroethene, oxidized, polymerized. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 1,1,2-2-TETRAFLUOROETHENE, OXIDIZED, PO4 LYMERIZED. 

5 (a) IN GENERAL.—Heading 9902.23.14 of the Har6 monized Tariff Schedule of the United States (relating to 

7 1,1,2-2-tetrafluoroethene, oxidized, polymerized) is 

8 amended by striking the date in the effective period col9 umn and inserting ‘‘12/31/2015’’. 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 2977 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
SCWC-18-0000352

IN THE SUPREME COURT OF THE STATE OF HAWAII

PO,

Petitioner/Appellant-Appellant,

vs.

CHILD SUPPORT ENFORCEMENT AGENCY, STATE OF HAWAIʻI and JK,

Respondents/Appellees-Appellees.

CERTIORARI TO THE INTERMEDIATE COURT OF APPEALS

(CAAP-18-0000352; FC-AP NOS. 17-1-001 and 17-1-002)

ORDER REJECTING APPLICATION FOR WRIT OF CERTIORARI

(By: Recktenwald, C.J., Nakayama, McKenna, Wilson, and Eddins JJ.)

Petitioner/Appellant-Appellant PO’s application for 

writ of certiorari, filed on April 20, 2021, is hereby rejected. 

DATED: Honolulu, Hawai‘i, May 28, 2021.

/s/ Mark E. Recktenwald

/s/ Paula A. Nakayama

/s/ Sabrina S. McKenna 

/s/ Michael D. Wilson

/s/ Todd W. Eddins

Electronically Filed

Supreme Court

SCWC-18-0000352

28-MAY-2021

11:06 AM

Dkt. 3 ODAC
Unassociated Document



Exhibit 4.8.75 - Document List - COVER PAGE OF INTERIOR DECORATION






 



	


	
SUNTEC Cleanroom & HVAC


Engineering Co., Ltd


	
 


 


 

	 
	
 



LIST OF DRAWINGS







New Plant Project of Shenyang Sunshine Pharmaceutical Company Limited







Production Workshop







Design of Working Drawings







Clean Decoration




 








	
Project


Principal

	 	
Checked by

	    	
Authorized


by

	 	
Date

	
2009.05.15
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 13-41331

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

ROBERTO ALFONSO RODRIGUEZ-CLAUDIO,

Defendant-Appellant

Appeal from the United States District Court

for the Southern District of Texas

USDC No. 7:13-CR-1241-1

Before DAVIS, CLEMENT and HAYNES, Circuit Judges.

PER CURIAM:*

The Federal Public Defender appointed to represent Roberto Alfonso 

Rodriguez-Claudio has moved for leave to withdraw and has filed a brief in 

accordance with Anders v. California, 386 U.S. 738 (1967), and United States 

v. Flores, 632 F.3d 229 (5th Cir. 2011). Rodriguez-Claudio has not filed a 

response. We have reviewed counsel’s brief and the relevant portions of the 

record reflected therein. We concur with counsel’s assessment that the appeal 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

July 18, 2014

Lyle W. Cayce

Clerk

 

 Case: 13-41331 Document: 00512704216 Page: 1 Date Filed: 07/18/2014
13-41331

presents no nonfrivolous issue for appellate review. Accordingly, counsel’s 

motion for leave to withdraw is GRANTED, counsel is excused from further 

responsibilities herein, and the APPEAL IS DISMISSED. See 5TH CIR. R. 42.2.

2

 Case: 13-41331 Document: 00512704216 Page: 2 Date Filed: 07/18/2014
Letter Agreement



 Exhibit 10.3 
  


					
	



	 		 	  
 Sunoco Logistics Partners L.P.

1818 Market Street, Suite 1500
 Philadelphia, PA
19103-3615
 866 248 4344


  
 November 2, 2011 

Michael J. Hennigan 
 President and Chief
Operating Officer 
 Sunoco Partners LLC 

1818 Market Street 
 Philadelphia, PA 19103

 Dear Mike: 
 In recognition of your
valuable contributions as President and Chief Operating Officer of Sunoco Partners LLC (the “Company”), we are restructuring certain benefits to which you will be entitled in the event the Company terminates your employment without
cause prior to your becoming retirement eligible (a “Pre-Retirement Termination”). Our goal is to ensure that with respect to these benefits you receive similar treatment to which you would have been entitled had you otherwise been
eligible to retire from the Company at the time of termination. 
 In particular, upon a Pre-Retirement Termination, you will be entitled to the
following: 
  

	 	-	Restricted Units. Notwithstanding any provision to the contrary in a Restricted Unit Agreement or other similar award agreement between you and the
Company (such agreements, “Restricted Unit Agreements”), any Restricted Units granted to you under the Sunoco Partners LLC Long Term Incentive Plan as of the date of a Pre-Retirement Termination (whether performance vested, time
vested, or otherwise conditioned upon your continued employment) shall not be forfeited, but shall continue to vest and be held by you, and shall be paid out at such time and in such manner as though no Pre-Retirement Termination occurred and you
had continued in the employment of the Company for the applicable restricted period. Except as expressly provided in this letter, all other terms and conditions of your Restricted Unit Agreements, including any performance metrics to be applied in
determining the number of Restricted Units earned thereunder, shall continue to apply and remain in full force and effect. 

  

	 	-	Post Employment Medical Benefits. The Company currently subsidizes medical benefits under its current plan for employees who are at least 55 years of age
and have a minimum of 10 years of service. In the event of a Pre-Retirement Termination, the Company will provide you access to post-employment medical benefits provided under this plan and in lieu of the Company subsidy, you will receive a lump sum
payment equal to the net present value of $150,000 as of the date of the Pre-Retirement Termination. 








 Except as otherwise provided in this letter, the terms and conditions applicable to other compensation and
executive benefits, if any, to which you may be entitled shall remain unchanged. 
 Please acknowledge your agreement and acceptance of the
terms of this letter by countersigning a copy of this letter and returning it to me. 
 Sincerely, 

			
	
		
		 	/s/ Lynn L. Elsenhans
		 	 Lynn L. Elsenhans

Chairman & Chief Executive Officer


 Acknowledged and agreed to 
 this 2nd day of November, 2011 
  

	
	/s/ Michael J. Hennigan
	Michael J. Hennigan
	President & Chief Operating Officer
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
STATEMENTS OF CONSOLIDATED OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                      73,691,000
<SECURITIES>                               299,551,000
<RECEIVABLES>                               29,070,000
<ALLOWANCES>                                 5,722,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                           222,898,000
<PP&E>                                     131,767,000
<DEPRECIATION>                              37,717,000
<TOTAL-ASSETS>                             579,514,000
<CURRENT-LIABILITIES>                      138,004,000
<BONDS>                                     66,612,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        89,000
<OTHER-SE>                                 226,161,000
<TOTAL-LIABILITY-AND-EQUITY>               579,514,000
<SALES>                                              0
<TOTAL-REVENUES>                           423,619,000
<CGS>                                                0
<TOTAL-COSTS>                              388,587,000
<OTHER-EXPENSES>                             1,568,000 <F1>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           3,924,000
<INCOME-PRETAX>                             32,676,000
<INCOME-TAX>                                 8,234,000
<INCOME-CONTINUING>                         24,442,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                24,442,000
<EPS-PRIMARY>                                     1.38
<EPS-DILUTED>                                     0.00
<FN>
<F1>MINORITY INTERESTS IN SUBSIDIARY LOSS
</FN>
        

</TABLE>
J~`~ ED STqT

~

S 

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

$ ~ Q WASHINGTON, D.C. 20460 

z z 

3~ ~o 

PROS~

G

~ C 

JUL 1 5 2"M 

Mr. J. R. Stroble 

Manager, National TRU Program 

U.S. Department of Energy 

P.O. Box 3090 

Carlsbad, New Mexico 88221-3090 

Dear Mr. Stroble: 

OFFICE OF 

AIR AND RADIATION 

On September 30, 2013 the U.S. Department of Energy (DOE), Carlsbad Field Office (CBFO), 

requested as a Tier 1(T1) change, for the U.S. Environmental Protection Agency's approval, to add 

additional containers (also referred to as Lot 5C) to a previously approved remote-handled (RH) waste 

stream (ID-HFEF-S5400-RH). With this letter EPA approves the requested Tier 1(T1) change to add 

Lot 5C waste to the approved RH waste stream. We base our approval on the evaluation elements 

discussed in the enclosed report (EPA Air pocket No. A-98-49; II-A4-185). 

If you have any questions regarding this approval, please contact Rajani Joglekar at (202) 343-9462 or 

Ed Feltcorn at (202) 343-9422. 

Sincerely, 

Tom Peake, Director 

Center for Waste Management and Regulations 

Enclosure 

cc: Electronic Distribution 

Joe Franco, CBFO 

Court Fesmire, CBFO 

Norma Castaneda, CBFO 

Tom Morgan, CBFO 

Mike Brown, CBFO QA 

Site Documents 

Intemet Address (URL) • http://www.epa.gov 

Recycled/Recyclable 9 Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper
II 

112TH CONGRESS 

1ST SESSION S. 305 

To repeal a prohibition on the use of certain funds for the termination 

of the Constellation program of the National Aeronautics and Space 

Administration. 

IN THE SENATE OF THE UNITED STATES 

FEBRUARY 8, 2011 

Mr. NELSON of Florida (for himself and Mrs. HUTCHISON) introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and Transportation 

A BILL 

To repeal a prohibition on the use of certain funds for 

the termination of the Constellation program of the National Aeronautics and Space Administration. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. REPEAL OF THE PROHIBITION ON USE OF CER4 TAIN FUNDS FOR TERMINATION OF THE CON5 STELLATION PROGRAM OF THE NATIONAL 

6 AERONAUTICS AND SPACE ADMINISTRATION. 

7 The Science Appropriations Act, 2010 (title III of di8 vision B of Public Law 111–117) is amended under the 


Emcdonald on DSK2BSOYB1PROD with BILLS
2 

•S 305 IS 

1 heading ‘‘EXPLORATION’’ (123 Stat. 3143) by striking 

2 the provisos. 

3 SEC. 2. TERMINATION AUTHORITY FOR CERTAIN CON4 TRACTS. 

5 The Administrator of the National Aeronautics and 

6 Space Administration may terminate any contract under 

7 the Constellation program that cannot be modified to com8 ply with the requirements of sections 302, 303, and 304 

9 of the National Aeronautics and Space Administration Au10 thorization Act of 2010 if the Administrator publishes the 

11 finding in the Federal Register not less than 30 days be12 fore the effective date of the termination and transmits 

13 a copy of the finding to the Senate Committee on Com14 merce, Science, and Transportation, the House of Rep15 resentatives Committee on Science, Space, and Tech16 nology, and the House and Senate Committees on Appro17 priations. 

Æ 


Emcdonald on DSK2BSOYB1PROD with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Centers for Disease Control and Prevention

                    Correction: This notice was published in the                     **Federal Register**                     on April 13, 2009, Volume 74, Number 69, Page 16878. The times and participant pass code has been changed to the following:                

*Times and Dates:*                         8 a.m.-8:15 a.m., April 22, 2009 (Open); 8:15 a.m.-4 p.m., April 22, 2009 (Closed).                    

*Place:*                         Teleconference, toll free: (877) 468-4185, Participant.                         *Passcode:*                         4475689.                    

*Contact Person For More Information:*                         Jane Suen, Dr.P.H., M.S., NCIPC, CDC, 4770 Buford Highway, NE., Mailstop F-62, Atlanta, Georgia 30341,                         *Telephone:*                         (770) 488-4281.                    

                        The Director, Management Analysis and Services Office, has been delegated the authority to sign                         **Federal Register**                         notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.                    

Dated: April 15, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9-9188 Filed 4-20-09; 8:45 am]

BILLING CODE 4163-18-P
Exhibit 32.2



Statement of Chief Financial Officer

Pursuant
to Section 1350 of Title 18 of the United States Code



Pursuant
to Section 1350 of Title 18 of the United States Code, the undersigned, James D. Brown, the Treasurer and Chief Financial Officer of NutriSystem, Inc. (the Company), hereby certifies that:



| | 1) | The Companys Form 10-Q Quarterly Report for the period ended September 30, 2003 (the Report) fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934; and
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|Dated: November 3, 2003 |  |  |  | /S/ JAMES D. BROWN                   
|----------------------- |  |  |  | -------------------------------------
|                        |  |  |  | Treasurer and Chief Financial Officer
52. "Volatile organic compounds" means the definition ofvolatile organic compounds in 40 Code ofFederal Regulations 51.1OO(s) as itexists on January 1, 2012, which is incorporated by reference.

History: Amended effective October 1, 1987; January 1, 1989; June 1, 1990; June 1, 1992; March 1, 1994; December 1, 1994; August 1, 1995; January 1, 1996; September 1, 1997; September 1, 1998; June 1, 2001; March 1, 2003; January 1, 2007; April 1, 2009; April 1, 2011; January 1, 2013. General Authority: NDCC 23-25-03 Law Implemented: NDCC 23-25-03

33-15-01-05. Abbreviations. The abbreviations used in this article have the following meanings:PM10 - particulate matterwith an aerodynamicdiameterlessthan orequal to 10 micrometers
[Federal Register Volume 74, Number 75 (Tuesday, April 21, 2009)]
[Notices]
[Page 18250]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-8970]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Distributed Sensor Technologies

    Notice is hereby given that, on March 9, 2008, pursuant to section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Distributed Sensor Technologies 
has filed written notifications simultaneously with the Attorney 
General and the Federal Trade Commission disclosing (1) The identities 
of the parties to the venture and (2) the nature and objectives of the 
venture. The notifications were filed for the purpose of invoking the 
Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances.
    Pursuant to section 6(b) of the Act, the identities of the parties 
to the venture are: Distributed Sensor Technologies, Inc., Santa Clara, 
CA; Redfern Integrated Optics, Inc., Santa Clara, CA; Optiphase, Inc., 
Van Nuys, CA; and University of Illinois, Chicago, Chicago, IL. The 
general area of Distributed Sensor Technologies' planned activity is to 
develop and integrate technologies that can be used to measure civil 
structure condition monitoring. The method being developed is utilizing 
distributed fiber sensing technology.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. E9-8970 Filed 4-20-09; 8:45 am]
BILLING CODE 4410-11-P
Amendment to Device Development and Manufacturing Agreement



 Exhibit 10.1 
 Confidential 
 AMENDMENT TO DEVICE DEVELOPMENT AND 

MANUFACTURING AGREEMENT 
 THIS AMENDMENT (“Amendment”) is effective as of the
8th day of July, 2011 and is by and between AMYLIN
PHARMACEUTICALS, INC., a Delaware corporation (“AMYLIN”), and ELI LILLY AND COMPANY, an Indiana corporation (“LILLY”). 
 AMYLIN and LILLY have entered into a Device Development and Manufacturing Agreement effective as of July 1, 2003 (the “Agreement”), and desire to amend the Agreement in accordance with
section 16.5 of the Agreement as described below. 
 For good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, AMYLIN and LILLY agree as follows: 
  

	 	1.	The fifth sentence of Section 5.4 of the Agreement which states: 

 Amylin will submit each such written purchase order to Lilly at least ninety (90) days in advance of the date specified in each purchase order by which delivery of the Devices is required.

  

	 	2.	is deleted and replaced in its entirety with the following sentence: 

 Amylin will submit each such written purchase order to Lilly at least sixty (60) days, in advance of the date specified in each purchase order by which delivery of the Devices is required.

  

	 	3.	All other terms and conditions of the Agreement remain in full force and effect. 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date written above. 
  

									
	Eli Lilly and Company	 		 	Amylin Pharmaceuticals, Inc.
					
	By:	 	 /s/ Maria Crowe
	 		 	By:	 	 /s/ Paul Marshall

	Name:  	 	Maria Crowe	 		 	Name:  	 	Paul Marshall
	Title:	 	VP Drug Products Manufacturing	 		 	Title:	 	Sr. Vice President, Operations
Exhibit
32.1




CERTIFICATE
PURSUANT TO 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002




In
connection with the quarterly report of HealthWarehouse.com, Inc. (the
“Company”) on Form 10-Q for the three months ended March 31, 2010 as filed with
the Securities and Exchange Commission (the “Report”), I, Lalit Dhadphale,
President and Chief Executive Officer, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that:




1.
            The Report fully complies with
      the requirements of section 13(a) or 15(d) of the Securities Exchange Act
      of 1934; and





2.
            The information contained in the
      Report fairly presents, in all material respects, the financial condition
      and results of operations of the
Company.




May
      17, 2010
            /s/ Lalit DhadphaleLalit
      DhadphalePresident
      and Chief Executive Officer




A signed
original of this written statement required by section 906 has been provided to
HealthWarehouse.com, Inc. and will be retained by HealthWarehouse.com, Inc. and
furnished to the Securities and Exchange Commission or its staff upon
request.